Endoscopic therapy and curative effect in pituitary adenoma patients complicated by acromegalic cardiomyopathy
- PMID: 29238923
- DOI: 10.1007/s10143-017-0936-7
Endoscopic therapy and curative effect in pituitary adenoma patients complicated by acromegalic cardiomyopathy
Abstract
The study aimed to retrospectively analyze the clinical characteristics of patients with pituitary adenomas complicated by acromegalic cardiomyopathy and to evaluate the effect of endoscopic surgery. Eighty-six pituitary adenoma patients complicated by acromegalic cardiomyopathy who were treated with endoscopic surgery in the First Affiliated Hospital of Soochow University from January 2010 to December 2016 were enrolled. We noted patient clinical characteristics and explored the relationships with surgical treatment. Before and after surgery, all patients underwent an examination of pituitary endocrinology, brain magnetic resonance (MR), and echocardiography. The serum levels of growth hormone (GH), left ventricular end-diastolic diameter (LVIDd), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), left ventricular ejection fraction (EF), and mitral valve (E/A ratio) were examined with non-invasive methods, and the results were compared. Of the 86 patients, there were 23 with microadenomas, 27 with large adenomas, and 36 with giant adenomas. There were 28 patients with invasive adenomas and 58 with non-invasive adenomas. The pre-operative mean GH level was 71.23 ± 3.29 μg/L, which was positively correlated with tumor volume (r = 0.751, P < 0.01). Via trans-sphenoidal endoscopic pituitary adenoma resection, 51 patients underwent total tumor resections, 25 underwent subtotal resections, 8 underwent major part resections, and 2 underwent partial resections. After surgery, the GH mean level was 3.81 ± 1.03 μg/L, which was significantly different (t = 3.72, P < 0.01) from the pre-operative level. Cardiac function indices, including LVIDd, IVST, LVPWT, E/A, and EF, were significantly improved. The long-term curative rate was 39.17% and the remission rate was 77.29%. For pituitary adenoma patients complicated by acromegalic cardiomyopathy, endoscopic surgery resulted in a good curative effect and the growth hormone levels were maintained, which can significantly improve cardiac structure and function.
Keywords: Acromegalic cardiomyopathy; Endoscopic surgery; Growth hormone; Pituitary adenoma.
Similar articles
-
Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.Neurosurg Focus. 2020 Jun;48(6):E10. doi: 10.3171/2020.3.FOCUS2080. Neurosurg Focus. 2020. PMID: 32480366
-
Acromegaly without imaging evidence of pituitary adenoma.J Clin Endocrinol Metab. 2010 Sep;95(9):4192-6. doi: 10.1210/jc.2010-0570. Epub 2010 Jul 7. J Clin Endocrinol Metab. 2010. PMID: 20610592 Free PMC article.
-
Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas.Neurosurg Focus. 2010 Oct;29(4):E6. doi: 10.3171/2010.7.FOCUS10173. Neurosurg Focus. 2010. PMID: 20887131
-
Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.J Neurosurg. 2013 Dec;119(6):1467-77. doi: 10.3171/2013.8.JNS13224. Epub 2013 Sep 27. J Neurosurg. 2013. PMID: 24074496 Review.
-
Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature.J Neurosurg. 2018 Aug;129(2):404-416. doi: 10.3171/2017.2.JNS162673. Epub 2017 Sep 1. J Neurosurg. 2018. PMID: 28862548
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical